Table 1 Patient characteristics
All (n = 483) | Men (n = 95) | Women (n = 388) | Elderly (n = 235) | Non-elderly (n = 248) | |
|---|---|---|---|---|---|
Age, years | 64.3 (11.7) | 66.2 (11.2) | 63.8 (11.7) | 73.9 (6.0) | 55.1 (7.7) |
Women, n (%) | 388 (80.3) | 0 (0.0) | 388 (100.0) | 180 (76.6) | 208 (83.9) |
DAS28-CRP, score, median (IQR) | 2.6 (1.8–3.5) | 2.5 (1.8–3.3) | 2.6 (1.7–3.5) | 2.4 (1.7–3.2) | 2.6 (1.9–3.8) |
Seropositive, n (%) | 328 (74.7) | 59 (74.7) | 269 (74.7) | 150 (77.7) | 178 (72.4) |
Disease duration, years, median (IQR) | 13.0 (9.0–21.0) | 12.0 (8.0–19.0) | 14.0 (9.0–22.0) | 15.0 (9.0–24.0) | 13.0 (8.0–19.0) |
Current GC dose, n (%)a | |||||
0 mg/d | 157 (32.5) | 18 (18.9) | 139 (35.8) | 81 (34.5) | 76 (30.6) |
> 0 to < 5 mg/d | 97 (20.1) | 22 (23.2) | 75 (19.3) | 51 (21.7) | 46 (18.5) |
5 mg/d | 151 (31.3) | 34 (35.8) | 117 (30.2) | 72 (30.6) | 79 (31.9) |
> 5 to ≤ 7.5 mg/d | 25 (5.2) | 7 (7.4) | 18 (4.6) | 9 (3.8) | 16 (6.5) |
> 7.5 mg/d | 53 (11.0) | 14 (14.7) | 39 (10.1) | 22 (9.4) | 31 (12.5) |
Cumulative dose, g, median (IQR) | 9.5 (3.4–24.6) | 10.4 (3.8–25.6) | 9.4 (3.2–24.6) | 9.2 (3.2–26.6) | 9.7 (3.6–23.0) |
Cumulative duration of GC use, years, median (IQR) | 5.8 (2.0–13.0) | 5.0 (2.5–12.1) | 6.0 (2.0–13.0) | 5.6 (2.0–14.0) | 6.0 (2.0–11.2) |
DMARD use, n (%) | 421 (87.2) | 82 (86.3) | 339 (87.4) | 207 (88.1) | 214 (86.3) |
csDMARDs | 312 (64.6) | 61 (64.2) | 251 (64.7) | 158 (67.2) | 154 (62.1) |
bDMARDs | 183 (37.9) | 34 (35.8) | 149 (38.4) | 81 (34.5) | 102 (41.1) |
tsDMARDs | 34 (7.0) | 6 (6.3) | 28 (7.2) | 9 (3.8) | 25 (10.1) |
Alcohol consumption, n (%) | |||||
None | 231 (48.5) | 37 (38.9) | 194 (50.9) | 116 (50.7) | 115 (46.6) |
Irregular/infrequent | 219 (46.0) | 47 (49.5) | 172 (45.1) | 96 (41.9) | 123 (49.8) |
Occasional | 23 (4.8) | 9 (9.5) | 14 (3.7) | 16 (7.0) | 7 (2.8) |
Frequent | 3 (0.6) | 2 (2.1) | 1 (0.3) | 1 (0.4) | 2 (0.8) |
Smoking, n (%) | |||||
Never | 230 (48.0) | 38 (40.0) | 192 (50.0) | 123 (53.0) | 107 (43.3) |
Former | 165 (34.4) | 36 (37.9) | 129 (33.6) | 86 (37.1) | 79 (32.0) |
Current | 84 (17.5) | 21 (22.1) | 63 (16.4) | 23 (9.9) | 61 (24.7) |
Body Mass Index, kg/m2 | 27.6 (5.4) | 28.1 (3.5) | 27.5 (5.8) | 27.6 (5.2) | 27.6 (5.7) |
C-reactive protein mg/l, median (IQR) | 2.3 (0.8–5.6) | 4.6 (1.4–13.8) | 2.1 (0.7–4.7) | 2.6 (1.0–7.5) | 1.7 (0.7–5.0) |
Vitamin D supplementation, n (%) | 403 (83.4) | 80 (84.2) | 323 (83.2) | 200 (85.1) | 203 (81.9) |
Calcium supplementation, n (%) | 33 (6.8) | 9 (9.5) | 24 (6.2) | 14 (6.0) | 19 (7.7) |
Serum 25-OH vitamin D3, n (%) | |||||
> 50 nmol/l | 395 (87.4) | 80 (87.9) | 315 (87.3) | 199 (90.5) | 196 (84.5) |
25–50 nmol/l | 54 (11.9) | 11 (12.1) | 43 (11.9) | 19 (8.6) | 35 (15.1) |
< 25 nmol/l | 3 (0.7) | 0 (0.0) | 3 (0.8) | 2 (0.9) | 1 (0.4) |
Anti-osteoporotic therapy, n (%) | |||||
Bisphosphonates | 63 (13.0) | 11 (11.6) | 52 (13.4) | 46 (19.6) | 17 (6.9) |
Denosumab | 17 (3.5) | 1 (1.1) | 16 (4.1) | 14 (6.0) | 3 (1.2) |
Teriparatide | 3 (0.6) | 0 (0.0) | 3 (0.8) | 1 (0.4) | 2 (0.8) |
Prior vertebral fracture, n (%)b | 46 (9.5) | 11 (11.6) | 35 (9.0) | 34 (14.5) | 12 (4.8) |
Prior non-vertebral fracture, n (%)b | 255 (52.8) | 45 (47.4) | 210 (54.1) | 121 (51.5) | 134 (54.0) |
Family history of osteoporosis, n (%) | 107 (30.1) | 11 (15.9) | 96 (33.4) | 40 (24.5) | 67 (34.7) |
Family history of osteoporotic fracture, n (%) | 46 (13.1) | 3 (4.3) | 43 (15.2) | 20 (12.4) | 26 (13.7) |
Minimum T-score | -1.7 (1.1) | -1.6 (1.1) | -1.7 (1.1) | -1.9 (1.1) | -1.4 (1.1) |
Osteoporosis by DXA, n (%) | 113 (23.4) | 21 (22.1) | 92 (23.7) | 68 (28.9) | 45 (18.1) |